乌司他丁联合奥曲肽治疗急性重症胰腺炎的临床效果观察

目的研究乌司他丁联合奥曲肽治疗急性重症胰腺炎的临床效果。方法在本院收治的急性重症胰腺炎患者中抽选78例开展研究,所有患者均为2015年8月~2016年12月期间入院,依据红蓝球分组法对上述患者进行分组,接受奥曲肽治疗的患者为对照组,在其基础上联合乌司他丁治疗的患者为观察组,对比两组患者的生化指标、住院天数、腹痛持续时间、禁食时间以及并发症发生情况。结果观察组患者的总蛋白(62.29±7.63)g/L、血红蛋白(134.28±7.58)g/L以及血清白蛋白(33.29±4.67)g/L均明显较对照组优,其禁食时间(7.46±1.57)d与腹痛持续时间(8.19±2.83)d均明显较对照组短,住院天数(20.36±2.68)d较对照组少(P0.05);两组患者的不良反应发生率比较差异无统计学意义(P0.05)。结论乌司他丁联合奥曲肽治疗急性重症胰腺炎的临床疗效显著,值得临床广泛应用。

Clinical effect observation of ulinastatin combined with octreotide in treatment of acute severe pancreatitis

Objective To observe the clinical effect of ulinastatin combined with octreotide in the treatment of acutesevere pancreatitis. Methods A total of 78 patients with acute severe pancreatitis admitted in our hospital were enrolled in the study. All patients were hospitalized during the period from August 2015 to December 2016. The patients were grouped according to the red-ball grouping method. The patients who received octreotide were selected as the control group. The patients who were treated with ulinastatin combined with octreotide were selected as the observation group.The biochemical indexes, length of hospital stay, duration of abdominal pain, fasting time and complications were compared between the two groups. Results The total protein was (62.29±7.63)g/L, hemoglobin was (134.28±7.58)g/L and serum albumin was (33.29 ±4.67)g/L in the observation group was significantly better than that in the control group.The fasting time was (7.46±1.57) d and duration of abdominal pain was (8.19±2.83) d in the observation group was significantly shorter than that of the control group. And the number of days of hospitalization was(20.36±2.68) d in the observation group was less than that of the control group(P<0.05). There was no significant difference in the adverse reactions probability between two groups of patients(P>0.05). Conclusion Ulinastatin combined with octreotide in the treatment of acute severe pancreatitis has significant clinical efficacy, and is widely used in clinic in the future.